MAB Discovery Enters Into an Agreement with Top 20 Global Pharma Company

MAB Discovery has announced that they have initiated two independent research collaborations with a US oncology focused biotech and a top 20 pharmaceutical company.

Employing its unique discovery platform, MAB Discovery will deliver a number of monoclonal antibodies to partner selected targets. Financial terms were not disclosed in either case.

MAB Discovery employs natural immunization of wild type animals (rabbits and rats), followed by fully automated single B cell cloning and PCR methods to discover high affinity monoclonals covering extensive epitope space.

Large and diverse panels of antibodies are created from B cells isolated at various times post immunization.

The power of the MAB Discovery platform resides in the vast number of high quality monoclonals from which to choose candidates with desired specificity and functionality.

In the case of rabbits, which have been well recognized over the years as excellent sources of high quality antibodies to virtually any antigen, the derived monoclonals are of extreme high affinity (<1nM), obviating the need for time-consuming affinity maturation campaigns with uncertain outcomes.

Applications for the MAB Discovery platform range from discovery of monoclonals to novel and difficult targets (eg, GPCRs, ion channels), to finding agents suitable for ADC strategies, to making "biobetters", etc.

"I am very pleased with the speed and efficiency by which our CEO, Dr. Stephan Fischer, and his team have been able to establish and validate the platform and to launch these important collaborations", said Dr. Lee Babiss, Chairman of MAB Discovery and CSO of PPD.

Dr. Babiss continued, "Companies such as MAB Discovery are positioned to take advantage of the increased outsourcing of discovery by large pharmas."